Prescient Therapeutics PTX-200 Breast Cancer Trial Progresses

17th February 2016, ASX announcement

PTX-200 Breast Cancer Trial Progress

• Phase Ib breast cancer trial enters expansion cohort
• H.Lee Moffitt Cancer Center joins trial recruitment

Melbourne, Australia 17 February 2016: Clinical stage oncology company Prescient Therapeutics Ltd (PTX) is pleased to announce that the last patient (patient 17) has been dosed in the escalation stage of its Akt inhibition Phase Ib breast cancer trial at Montefiore Cancer Center of Albert Einstein University in New York (Albert Einstein University) under the guidance of Professor Joseph Sparano. The trial is targeting women with metastatic and locally advanced HER2 negative breast cancer.

This latest patient received treatment on the third dose level and had no dose limiting toxicity (DLT). As a result, the recommended Phase II dose (RPTD) for this trial has been determined as  35 mg/m2 PTX-200, together with chemotherapy.

As part of this expansion stage, PTX is pleased to announce that the H.Lee Moffitt Cancer Center (Moffitt) in Tampa, Florida will shortly join Albert Einstein University in the Phase Ib expansion cohort and the Phase II trial, and is expected to soon commence recruitment.

Dr. Heather Han, a medical oncologist specializing in breast cancer in the Center for Women’s Oncology at Moffitt, will conduct the study.

To read the full announcement, please click here.